Page 133 - ITPS-7-2

INNOSC Theranostics and
Pharmacological Sciences PI3K-α inhibitors for cancer immunotherapy

Landscape of phosphatidylinositol-3-kinase pathway 20. Backer JM. The regulation and function of class III PI3Ks:
alterations across 19 784 diverse solid tumors. JAMA Oncol. Novel roles for Vps34. Biochem J. 2008;410:1-17.
2016;2(12):1565-1573. doi: 10.1042/BJ20071427
doi: 10.1001/jamaoncol.2016.0891 21. Yadav RR, Guru SK, Joshi P, et al. 6-Aryl substituted
10. Vivanco I, Sawyers C. The phosphatidylinositol 3-Kinase-AKT 4-(4-cyanomethyl) phenylamino quinazolines as a new class
pathway in human cancer. Nat Rev Cancer. 2002;2:489-501. of isoform-selective PI3K-alpha inhibitors. Eur J Med Chem.
2016;122:731-743.
doi: 10.1038/nrc839
doi: 10.1016/j.ejmech.2016.07.006
11. Markman B, Dienstmann R, Tabernero J. Targeting the
PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget. 22. Hauptman N, Jevšinek D, Glavač D. Noncoding RNA alterations
2010;1:530-543. in cancer molecular pathways. In: Cancer and Noncoding RNAs.
Cambridge: Academic Press; 2018. p. 247-268.
doi: 10.18632/oncotarget.188
doi: 10.1016/b978-0-12-811022-5.00014-0
12. Courtney KD, Corcoran RB, Engelman JA. The PI3K
pathway as drug target in human cancer. J Clin Oncol. 23. Furet P, Guagnano V, Fairhurst RA, et al. Discovery of NVP-
2010;28:1075-1083. BYL719 a potent and selective phosphatidylinositol-3 kinase
alpha inhibitor selected for clinical evaluation. Bioorg Med
doi: 10.1200/JCO.2009.25.3641 Chem Lett. 2013;23(13):3741-3748.
13. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. doi: 10.1016/j.bmcl.2013.05.007
Phosphoinositide 3-kinases: A conserved family of signal
transducers. Trends Biochem Sci. 1997;22:267-272. 24. Nunnery SE, Mayer IA. Management of toxicity to isoform
α-specific PI3K inhibitors. Ann Oncol . 2019;30:x21-x26.
doi: 10.1016/S0968-0004(97)01061-X
doi: 10.1093/annonc/mdz440
14. Reif K, Okkenhaug K, Sasaki T, Penninger JM,
Vanhaesebroeck B, Cyster JG. Cutting edge: Differential 25. Utermark T, Rao T, Cheng H, et al. The p110α and p110β
roles for phosphoinositide 3-Kinases, p110gamma and isoforms of PI3K play divergent roles in mammary
p110delta, in lymphocyte chemotaxis and homing. gland development and tumorigenesis. Genes Dev.
J Immunol. 2004;173:2236-2240. 2012;26(14):1573-1586.
doi: 10.4049/jimmunol.173.4.2236 doi: 10.1101/gad.191973.112
15. Williams R, Berndt A, Miller S, Hon WC, Zhang X. Form 26. Sabbah DA, Simms NA, Brattain MG, Vennerstrom JL,
and flexibility in phosphoinositide 3-kinases. Biochem Soc Zhong H. Biological evaluation and docking studies of
Trans. 2009;37(4):615-626. recently identified inhibitors of phosphoinositide-3-kinases.
Bioorg Med Chem Lett. 2012;22(2):876-880.
doi: 10.1042/BST0370615
doi: 10.1016/j.bmcl.2011.12.044
16. Engelman JA, Luo J, Cantley LC. The evolution of
phosphatidylinositol 3-kinases as regulators of growth and 27. Bhaskar BV, Rammohan A, Babu TM, et al. Molecular insight
metabolism. Nat Rev Genet. 2006;7:606-619. into isoform specific inhibition of PI3K-α and PKC-η with
dietary agents through an ensemble pharmacophore and
doi: 10.1038/nrg1879 docking studies. Sci Rep. 2021;11(1):12150.
17. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, doi: 10.1038/s41598-021-90287-3
Waterfield MD. Cellular function of phosphoinositide
3-Kinases: Implications for development, homeostasis, and 28. Ali AM, Makki AA, Ibraheem W, et al. Design of novel
cancer. Annu Rev Cell Dev Biol. 2001;17:615-675. phosphatidylinositol 3-kinase inhibitors for non-hodgkin’s
lymphoma: Molecular docking, molecular dynamics, and
doi: 10.1146/annurev.cellbio.17.1.615 density functional theory studies on gold nanoparticles.
18. Raffoul JJ, Kucuk O, Sarkar FH, Hillman GG. Dietary Molecules. 2023;28(5):2289.
agents in cancer chemoprevention and treatment. J Oncol. doi: 10.3390/molecules28052289
2012;2012:749310.
29. Dirican E, Akkiprik M. Phosphatidylinositol 3-kinase
doi: 10.1155/2012/749310 regulatory subunit 1 and phosphatase and tensin homolog
as therapeutic targets in breast cancer. Tumour Biol.
19. Kasala ER, Bodduluru LN, Barua CC, Sriram CS,
Gogoi R. Benzo(a)pyrene induced lung cancer: Role of 2017;39:101042831769552.
dietary phytochemicals in chemoprevention. Pharmacol doi: 10.1177/1010428317695529
Rep. 2015;67:996-1009.
30. Saldanha SN, Tollefsbol TO. The role of nutraceuticals in
doi: 10.1016/j.pharep.2015.03.004 chemoprevention and chemotherapy and their clinical

Volume 7 Issue 2 (2024) 23 doi: 10.36922/itps.2340